A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Latest Information Update: 09 Jun 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2021 Status changed from recruiting to completed.
- 29 Sep 2020 Planned number of patients changed from 30 to 25.
- 29 Sep 2020 Planned End Date changed from 1 Aug 2021 to 1 Aug 2023.